44 results about "Hematological malignancy" patented technology

Described herein are LAG3 specific single domain antibodies and binding molecules comprising such single domain antibodies, as well as nucleic acids encoding the same. Also provided are nucleic acids (e.g., mRNA) encoding such single domain antibodies and binding molecules and delivery vehicles (e.g., lipid nanoparticles) formulated with said nucleic acids. The disclosure also features methods of using such antibodies, binding molecules, nucleic acids, and delivery vehicles formulated with said nucleic acids to treat various diseases such as inflammatory diseases, T cell driven autoimmune diseases, and cancer (e.g., solid tumors or hematological malignancies).

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

This invention discloses a class of 2-(2-(quinolin-4-yloxy)ethyl)pyridazine-3(2H)-one compounds, their preparation methods, and applications. The structure of these compounds is shown in general formula (I). This invention also discloses that the above compounds have a significant inhibitory effect on interleukin-1 receptor-associated kinase 1 (IRAK1). These compounds can inhibit the proliferation of various tumor cells, including liver cancer, lung cancer, pancreatic cancer, gastric cancer, kidney cancer, colon cancer, esophageal cancer, glioblastoma, leukemia, multiple myeloma, and other solid tumors and hematological malignancies. This invention provides a new option for tumor treatment.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.

Described herein are methods of treating a hematological malignancy, including minimal residual disease in hematological malignancies, and methods of preventing relapse of hematological malignancies, the methods comprising administering an inflammasome modulator. In some embodiments the method of treatment comprises administering a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined herein.

The present disclosure relates to antibodies and antibody fragments specific for CCR2. As reactivity with marmoset CCR2, which is a species that is crucial to further preclinical and clinical development, is lost, almost all attempts to humanize the original antibody are notified as failure. The antibodies are useful in the treatment of inflammatory diseases, autoimmune diseases, hematological malignancies, and potentially other diseases.

The present disclosure discloses methods and systems for detecting cancer and / or determining tissue of origin of cancer. In some embodiments, a multi-classification cancer classifier is disclosed that is trained using a plurality of biological samples containing cfDNA fragments. The analysis system derives a feature vector for each sample, and the multi-classification classifier predicts a probabilistic likelihood for each of a plurality of cancer signal origin (CSO) classifications. In some embodiments, the plurality of CSO classifications include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples with high predictive scores are rejected from a training sample set. In another embodiment, the analysis system stratifies the sample according to a predicted score and applies a binary threshold cutoff value determined for each stratification.

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

Provided herein are formulations, processes, solid forms and methods of use (e.g., methods of treating a hematological malignancy) relating to salts of and solid forms comprising free base or salts of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione.

The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

The present invention relates to a combination product comprising a Bcl-2 / Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2 / Bcl-xL inhibitor of formula I-A and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. The invention also relates to the use of the aforementioned combination for the preparation of a medicament for the prevention and / or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and / or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.

This application relates to an anti-ROR1 antibody, an antibody-drug conjugate containing the antibody, a pharmaceutical composition and medical product containing the antibody-drug conjugate, and a method for producing and using the antibody-drug conjugate, wherein the antibody-drug conjugate is effective in treating and / or preventing ROR1-positive tumors, including hematological malignancies and solid tumors (e.g., cancers such as breast cancer and bladder cancer).

Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and / or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

Provided herein are compounds and isolated enantiomers useful for inhibiting telomerase, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising at least one such compound, isolated enantiomer, or pharmaceutically acceptable salt thereof. Also described is the use of such compounds, isolated enantiomers, or pharmaceutically acceptable salts thereof, and the use of pharmaceutical compositions comprising at least one such compound, isolated enantiomer, or pharmaceutically acceptable salt thereof, in methods of treating disorders or conditions such as cancer, where the cancer may be a hematological malignancy or a solid tumor.

A PI3K-delta inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of hematological malignancies in a subject, wherein the treatment comprises separate, sequential, or concurrent administration to the subject of i) the PI3K-delta inhibitor or a pharmaceutically acceptable salt thereof, and ii) a BCL-2 inhibitor or a pharmaceutically acceptable salt thereof. The treatment may also further comprise iii) separate, sequential, or concurrent administration to the subject of iii) further chemotherapeutic agents.

This invention discloses a pyrrolobenzene derivative compound, its preparation method, and its pharmaceutical application, belonging to the field of chemical pharmaceutical raw materials and formulation manufacturing technology. The compound has the structure shown. This compound specifically binds to the SGLT-2 protein through a pyrrolobenzene conjugated system, inhibiting its glucose transport function and affecting the IC50 of SGLT-2. 50 Values ​​range from 15 to 105 nM. Suitable for preparing drugs to treat non-alcoholic liver disease, solid tumors, hematological malignancies, and autoimmune diseases, especially effective against abnormal glucose and lipid metabolism in hepatocytes and energy deprivation in tumor cells. The compound possesses enhanced metabolic stability due to its deuterated group and can be formulated into tablets, capsules, injections, and other dosage forms.

Disclosed herein are combination therapies for treating hematological malignancies (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapeutic agents, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.

The invention discloses a polysubstituted amine compound, a pharmaceutical composition containing the polysubstituted amine compound and an application of the polysubstituted amine compound in tumor resistance. The structure of the polysubstituted amine compound is shown as a formula I in the specification. Through multiple experiments, the inventor of the invention proves that the compound disclosed by the invention has a remarkable inhibiting effect on FBXO44, and can be combined with the FBXO44 in cells to inhibit down-regulation of the FBXO44 on MTSS1, so that the formation of tumor cell microfilament skeletons is disturbed, and the compound has a strong anti-proliferation effect on gastric cancer cell strains such as NUGC4 and the like. Therefore, the compound disclosed by the invention can be used as an FBXO44 inhibitor to be applied to medicines for treating solid tumors or leukemia related to human or animal cell proliferation.

The invention belongs to the technical field of gene sequencing, and particularly relates to a library building kit and probe for detecting blood tumor related fusion genes. According to the library building kit, only a trace amount of total RNA is needed to be used for cDNA synthesis, the initial quantity of a template can be as low as 10 ng, so that a cDNA library is built, then the library is subjected to hybrid capture and enrichment by using an autonomously designed probe hematologic tumor fusion gene Panel (RA Panel), the time consumption is short, the efficiency is high, and simultaneous building and on-machine sequencing of 384 libraries can be realized. According to the rapid hybridization system of the library building kit, the shortest hybridization time can reach 30 min, the size of a finally obtained library fragment is about 200-400 bp, and the rapid hybridization system can be compatible with various Illumina sequencing platforms for sequencing. According to the invention, through a simple and easy-to-use solution of NGS sequencing while synthesis, rapid and accurate typing of fusion genes which may affect blood tumor diagnosis is realized.

The invention provides an immortalized T cell line SZ906 derived from peripheral blood of a hematoma patient as well as a preparation method and application of the immortalized T cell line SZ906. The immortalized T cell line SZ906 derived from the peripheral blood of the hematoma patient is preserved in Guangdong Microbial Culture Collection Center on December 25, 2025, and the preservation number is GDMCC No: 67533. The immortalized T cell line SZ906 derived from the peripheral blood of the hematoma patient, provided by the invention, can still keep good multiplication capacity and high survival rate in a long-time (more than one year) culture process, has strong cytotoxicity to tumor cells, and can kill the tumor cells and remove cells infected by pathogens.

The invention relates to an anti-CD33 single-domain antibody and application thereof. According to the invention, the anti-CD33 single-domain antibody specifically bound with CD33 is screened by using a biological gene engineering technology, and the antibody has good affinity and is used for treating hematological malignant tumors and other CD33 related diseases.

A method for diagnosing a disease in a subject, in particular a hematological malignancy or a solid tumor, comprising the steps of: isolating (21, 61) an extracellular vesicle precipitate (3a, 3b) obtained from a sample (2) of a biological fluid previously taken from the subject; measuring (31, 41, 51-52), from said precipitation, parameters representative of six biomarkers: (I) the size of the extracellular vesicles; (II) the total amount of extracellular vesicles; (III) an amount of extracellular vesicles expressing the first antigen on their own surface and (IV) an amount of extracellular vesicles expressing the first antigen and the second antigen; (V) an average fluorescence intensity for each of the antigens; and (VI) the nucleic acid content of the extracellular vesicles; first comparing a parameter representative of the biomarker with a corresponding critical value; based on the first comparison step, assigning a partial score to each parameter or to the six biomarkers; calculating a final score, namely the score of the subject, as the sum of the partial scores; a second comparison of the final score with at least one predetermined diagnostic threshold, preferably with two diagnostic thresholds, an upper diagnostic threshold and a lower diagnostic threshold; based on the second comparison step, a probabilistic diagnosis of the lesion is estimated. Under the background of personalized medical treatment, the combination of the six biomarkers overcomes the limitation of the prior art method caused by high clinical heterogeneity between subjects, which is specifically embodied in sensitivity to a given lesion; in other words, a certain biomarker, not other biomarkers, selected from the six biomarkers and related parameters of the biomarkers are different.

A synthetic protein switch is provided that has an active state and an inactive state and includes a C-terminal Src kinase (CSK) domain having an amino acid sequence that is at least 70% identical to, or a functional variant of, SEQ ID NO: 11 and a sensing domain, and wherein the synthetic protein switch reversibly converts from the inactive state to the active state upon interaction with an inducer and reversibly converts from the active state to the inactive state upon removal of the inducer. Also provided are methods for reversible modulation of T-cell signaling, treating a cytokine release syndrome (CRS), and treating a hematological malignancy using such synthetic protein switch. Further provided is a method of producing such synthetic protein switch, the method including transferring to a host cell or transfecting the host cell with a viral vector having a nucleic acid encoding the synthetic protein switch.

The present invention relates to a bispecific antibody comprising an anti-CD19 single-chain fragment variable and an anti-CD3 single-chain fragment variable. The present invention also relates to T cells secreting the bispecific antibody, method of preparation of T cells secreting the bispecific antibody and uses thereof in the treatment of a hematological malignancy selected from the group consisting of lymphoma, leukemia and myeloma.

The application discloses a general allogeneic CAR-NK cell preparation and application thereof, and belongs to the technical field of cell immunotherapy biological preparations. The preparation comprises pre-activated modified allogeneic CAR-NK cells, a composite protective agent system and a medicinal buffer, and is prepared from umbilical cord blood-derived NK cells through non-integrated CAR lentivirus transfection, cytokine combination pre-activation and liposome membrane anchoring HLA-G immune shielding modification. The composite protective agent system is created for the first time, and can simultaneously realize the functions of cryopreservation protection, in-vivo synergism and immunoregulation, and solve the defects of existing allogeneic CAR-NK preparations, such as dependence on gene editing, poor cryopreservation stability, high immunogenicity, short in-vivo survival time and insufficient anti-tumor activity, and can be used for preparing a therapeutic drug for CD19-positive hematological malignancies, and is suitable for industrialized development of "off-the-shelf" general cell treatment products.

This invention provides an antitumor agent that demonstrates efficacy against cancer cells expressing CD123, which has been reported to be overexpressed in malignant cells of a wide range of hematological malignancies. [Solution] Provided are an antibody or its antigen-binding fragment, an immune complex containing the antibody, and a method for using such CD123-binding molecules to diagnose and treat diseases such as B-cell malignancies, (a) an epitope within amino acids 101-346 of the human CD123 / IL3-Rα antigen, and (b) an antibody or its antigen-binding fragment that inhibits IL3-dependent proliferation of antigen-positive TF-1 cells.

The invention discloses a method for improving proliferation and activity of cytokine-induced killer cells, and belongs to the technical field of cellular immunity. According to the method, the human peripheral blood mononuclear cells are firstly cultured in the culture medium containing the cell factors, then the obtained CIK cells are cultured in the culture medium containing the cell factors and the PP2A inhibitor, the amplification efficiency of the CIK cells is improved through the PP2A inhibitor, and the proportion of CD3 + CD56 + cells in the CIK cells is increased; according to the invention, a cell signal transduction pathway regulator PP2A inhibitor is ingeniously introduced, and culture conditions are optimized, so that the amplification efficiency of CIK cells is remarkably improved, and the proportion of functional subgroups is improved. Meanwhile, on the basis of improving the cell performance, the preparation cost of the CIK cell is relatively reduced, and the CIK cell is particularly suitable for preparing a CIK cell preparation required by adoptive immunotherapy and can be widely applied to treatment of solid tumors and blood system tumors.

The invention belongs to the technical field of gene sequencing, and particularly relates to a library building kit and a probe for detecting hematologic tumor chemotherapy related gene polymorphism by using a hybrid capture method. According to the present invention, the genotype of the hematologic tumor chemotherapy related gene, the drug treatment effect, the toxicity and the metabolic capability related information can be rapidly obtained through the one-time detection; meanwhile, the library building kit is simple and convenient to operate and short in consumed time, and automatic detection is extremely easy to realize. The detection result completed by using the library building kit is accurate, and the library building kit has important reference significance for treatment and prognosis of hematologic tumor patients needing chemotherapy.